• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

15 August 2019

Baqsimi nasal powder ( glucagon), first treatment for severe hypoglycemia that can be administered without an injection


0 Comments4 Minutes

9 August 2019

Vitrakvi (larotrectinib), first ‘histology-independent’ treatment for solid tumours with a specific gene mutation


0 Comments4 Minutes

17 July 2019

Victoza, liraglutide, new treatment for children with type 2 diabetes


0 Comments4 Minutes

16 July 2019

Dupixent (dupilumab), first treatment for chronic rhinosinusitis with nasal polyps


0 Comments3 Minutes

10 July 2019

FDA approves Soliris (eculizumab), first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system


0 Comments5 Minutes

10 July 2019

FDA approves Xpovio (selinexor), new treatment for refractory multiple myeloma


0 Comments5 Minutes

31 May 2019

Piqray (alpelisib), first PI3K inhibitor for breast cancer


0 Comments6 Minutes

26 May 2019

Zolgensma (onasemnogene abeparvovec-xioi), innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality


0 Comments7 Minutes

18 May 2019

FDA approves Fragmin (dalteparin sodium) first anticoagulant for pediatric patients to treat potentially life-threatening blood clots


0 Comments4 Minutes

7 May 2019

Dengvaxia, the first vaccine approved by FDA for the prevention of dengue disease caused by all dengue virus serotypes


0 Comments6 Minutes

  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13

Warning:

A cybersecurity incident is under investigation. Please be carefull with emails or phone calls that correctly mention your name, role, or current transactions. Elixi’s crisis team is working to limit any harmful impact, as the security of our clients’ and suppliers’ data is Elixi’s top priority. For any clarification, you can contact: DPO@elixi-int.com

Si è verificato un evento di sicurezza informatica in corso di analisi. Vi invitiamo a prestare massima attenzione messaggi di posta elettronica o telefonate che citano correttamente il vostro nome, la funzione o operazioni realmente avvenute. Il crisis team di Elixi sta lavorando per limitare ogni conseguenza dannosa, perchè la sicurezza dei dati dei nostri clienti e dei fornitori è la nostra priorità di Elixi. Per ogni chiarimento potete contattare: DPO@elixi-int.com